The transcriptional activity of the androgen receptor (AR) is regulated by interaction with various coregulators, one of which is b-catenin. Interest in the role of b-catenin in prostate cancer has been stimulated by reports showing that it is aberrantly expressed in the cytoplasm and/or nucleus in up to 38% of hormone-refractory tumours and that overexpression of b-catenin results in activation of AR transcriptional activity. We have examined the effect of depleting endogenous b-catenin on AR activity using Axin and RNA interference. Axin, which promotes b-catenin degradation, inhibited AR transcriptional activity. However, this did not require the b-catenin-binding domain of Axin. Depletion of b-catenin using RNA interference increased, rather than decreased, AR activity, suggesting that endogenous b-catenin is not a transcriptional coactivator for the AR. The glycogen synthase kinase-3 (GSK-3)-binding domain of Axin prevented formation of a GSK-3-AR complex and was both necessary and sufficient for inhibition of AR-dependent transcription. A second GSK-3-binding protein, FRAT, also inhibited AR transcriptional activity, as did the GSK-3 inhibitors SB216763 and SB415286. Finally, inhibition of GSK-3 reduced the growth of AR-expressing prostate cancer cell lines. Our observations suggest a potential new therapeutic application for GSK-3 inhibitors in prostate cancer.
Introduction
Prostate cell growth and development are mediated by androgens and the androgen receptor (AR), a member of the nuclear receptor superfamily. The transcriptional activity of AR is regulated by interaction with various coregulators (reviewed in Cheshire and Isaacs, 2003; Cronauer et al., 2003) , one of which is b-catenin.
Evidence that increased levels of b-catenin lead to activation of AR transcriptional activity come largely from studies in which b-catenin is overexpressed (Truica et al., 2000; Mulholland et al., 2002; Yang et al., 2002) . However, the level of endogenous b-catenin is already very high in prostate cancer cells and stable expression of mutant b-catenin does not alter their proliferative response to androgen . Therefore, it is important to determine how endogenous b-catenin affects AR transcriptional activity in prostate cancer cells. Here we describe experiments addressing this question using Axin and RNA interference. Our results suggest that glycogen synthase kinase-3 (GSK-3), rather than b-catenin, is an important endogenous regulator of AR transcriptional activity.
GSK-3 is a serine/threonine kinase best known for its roles in glycogen metabolism, the Wnt signalling pathway and in neurological disorders (reviewed in Frame and Cohen, 2001; Grimes and Jope, 2001; Woodgett, 2001; Doble and Woodgett, 2003) . GSK-3 has been shown to be active in most resting cells and is subject to negative regulation by external stimuli. In response to growth factor stimulation, for example, kinases such as Akt inhibit GSK-3 by phosphorylation on serine 9 (Stambolic and Woodgett, 1994; Cross et al., 1995) . In some instances, GSK-3 has been shown to be activated by agents that promote phosphorylation on tyrosine 216 (Bhat et al., 2000) . GSK-3 can also be regulated by binding to the proteins Axin, FRAT (frequently rearranged in advanced T-cell lymphomas)/GBP and the Kaposi's sarcoma-associated herpesvirus latencyassociated nuclear antigen (Ikeda et al., 1998; Yost et al., 1998; Fujimuro et al., 2003) .
GSK-3 has numerous substrates, including a number of transcription factors such as c-Jun, c-myc, C/EBPs (CCAAT enhancer-binding proteins) and NF-ATc (nuclear factor of activated T cells). The effects of phosphorylation by GSK-3 tend to be inhibitory and include promotion of degradation and enhancement of nuclear export (for references see Frame and Cohen, 2001) . Thus, inhibition of GSK-3 often results in increased gene expression. However, there are examples where GSK-3 positively regulates gene expression, such as through CREB phosphorylation (Salas et al., 2003) . Here we show that GSK-3 positively regulates AR transcriptional activity. Furthermore, GSK-3 inhibitors inhibit the proliferation of prostate cancer cells, suggesting that these drugs might be useful in the treatment of patients with prostate cancer.
Results

Inhibition of AR transcriptional activity by Axin
Axin inhibits the Wnt signalling pathway by acting as a scaffold protein, bringing together a number of proteins, including b-catenin, APC and GSK-3, and thereby promoting phosphorylation and degradation of b-catenin (for references see Kikuchi, 2000; Gregory et al., 2001) . Ectopic expression of Axin is sufficient to inhibit Wnt/b-catenin signalling and is therefore often used as a tool to inhibit endogenous b-catenin function (Ross et al., 2000; Hsu et al., 2001; Reya et al., 2003) . In order to determine whether endogenous b-catenin functions as a coactivator for the AR in prostate cancer cells, we expressed Axin in CWR-R1 cells. This is a cell line derived from the CWR22 xenograft model for prostate cancer that expresses endogenous AR (Gregory et al., 2001) and high levels of b-catenin . For these studies we used a luciferase reporter plasmid driven by the MMTV promoter, which contains AR-binding sites, R1881 (a synthetic ligand for the AR) and a panel of previously characterized GFP-Axin expression constructs (Orme et al., 2003) ( Figure 1a) ; GFP was used as a negative control. As expected, compared with cells expressing GFP and treated with carrier ( Figure 1b , lane 1), addition of R1881 resulted in an increase in AR transcriptional activity ( Figure 1b, lane 2) . Expression of GFP-Axin resulted in a reduction in AR transcriptional activity (Figure 1b, lane 3) . This was consistent with studies in which b-catenin overexpression has been shown to activate AR (Truica et al., 2000; Mulholland et al., 2002; Pawlowski et al., 2002; Yang et al., 2002) . Mutation of a conserved proline residue in the GSK-3-binding domain of Axin (GFP-AxinP), which prevents binding to GSK-3 and also reduces binding to b-catenin (Smalley et al., 1999) , prevented the inhibition of AR transcriptional activity (Figure 1b . This mutant is useful because it cannot indirectly interact with b-catenin through endogenous APC (Hinoi et al., 2000) . GFP-Axin DAPC/Db inhibited AR transcriptional activity ( Figure 1b , lane 6) to the same extent as a mutant lacking only the APC-binding domain, GFP-Axin DAPC ( Figure 1b , lane 5) and GFP-Axin itself. These results suggest that the inhibition of AR transcriptional activity by Axin is independent of b-catenin and that the loss of inhibitory activity in GFP-AxinP results from its inability to bind GSK-3.
In order to determine if the GSK-3-binding domain of Axin is sufficient for the inhibition of AR activity, we expressed a construct of Axin comprising only the GSK- , GFP-Axin (3), GFP-AxinP (4), GFP-Axin DAPC (5) or GFP-Axin DAPC/Db-catenin (6), MMTVLuciferase and RSV-b-Gal. AR transcriptional activity was determined in extracts from cells grown in hormone-depleted medium in the absence (À) or presence ( þ ) of 10 nM R1881. (c) The GSK-3-binding domain of Axin is sufficient for inhibition of AR activity. CWR-R1 cells were transfected with empty vector (1 and 2), AX2 (3), AX2P (4) or AX2 plus pMT23 GSK-3 S9A (5), MMTV-Luciferase and RSV-b-Gal. Empty vector (pMT23) was included in transfections 1-4 to allow direct comparison with transfection 5. AR transcriptional activity was determined in extracts from cells grown in hormone-depleted medium either in the absence (À) or presence ( þ ) of 10 nM R1881. All experiments were done three or more times in triplicate. The error bars indicate standard deviation GSK-3 inhibition represses androgen receptor activity M Mazor et al 3-binding domain, AX2 (Smalley et al., 1999) . Relative to empty vector ( Figure 1c , lane 2), AX2 inhibited AR transcriptional activity (Figure 1c, lane 3) . As a control we used AX2 with a mutation in the conserved proline residue required for GSK-3 binding (AX2P), and we found that AX2P did not inhibit AR activity (Figure 1c , lane 4). Moreover, coexpression of constitutively active GSK-3 with AX2 rescued the inhibitory effects of AX2 on AR transcriptional activity (Figure 1c, lane 5) . Taken together, these results indicate that GSK-3, rather than b-catenin, is involved in the inhibitory effects of Axin on AR transcriptional activity.
Depletion of endogenous b-catenin does not inhibit endogenous AR transcriptional activity in prostate cancer cells
Our results using Axin suggest that endogenous b-catenin in prostate cancer cells does not affect AR activity. In order to test this possibility, we used a second approach to determine the effect of removing endogenous b-catenin on AR transcriptional activity. For these studies, we used a well-characterized b-catenin siRNA expression vector that has been shown to reduce b-catenin protein levels and inhibit b-catenin/Tcf transcriptional activity (van de Wetering et al., 2003) . We first used HCT 116 colon cancer cells, which have a stabilizing mutation in b-catenin, and pOT-Luciferase, a reporter plasmid with Tcf/LEF-1-binding sites. Figure 2c) . A second control siRNA expression vector (Control 2) had no effect on AR transcriptional activity, and the inhibitory effect was not observed in the absence of hormone (Figure 2c) .
In order to determine if the effects of b-catenin siRNA resulted from a reduction in the level of expression of cotransfected AR, Western blots were conducted after transfection (Figure 2e ). Expression of b-catenin siRNA led to a significant reduction in b-catenin protein (Figure 2e , upper panel, lanes 3 and 4). The depletion of b-catenin is likely to be more efficient than suggested by the Western blot since the extracts also contained b-catenin from untransfected cells, which comprise more than half the cell population. In the same extracts the expression level of AR was unaffected by expression of b-catenin siRNA (Figure 2e , lower panel), indicating that the inhibition of AR after depletion of b-catenin did not result from a reduction in AR protein levels.
We also examined the effects of depletion of b-catenin on endogenous AR activity in prostate cancer cells. The low transfection efficiency of the prostate cancer cell lines made it difficult to detect changes in b-catenin protein levels after expression of b-catenin siRNA. Therefore we used the reduction of b-catenin/Tcf transcriptional activity (Figure 2a ) as a measure of the efficiency of the b-catenin siRNA. Depletion of b-catenin did not inhibit endogenous AR transcriptional activity in CWR-R1 cells, LNCaP cells (Figure 2b ) or 22Rv1 cells ( Figure 2d ); in fact AR activity was significantly increased. These results suggest that the regulation of endogenous AR transcriptional activity by endogenous b-catenin differs from what has been observed in experiments where one or both of these proteins are ectopically expressed.
GSK-3 increases AR transcriptional activity
Axin deletion analysis suggested an important role for GSK-3 in the regulation of AR activity. Therefore, we assessed the effects of overexpressing GSK-3 on AR transcriptional activity. For these studies we used wildtype GSK-3, a constitutively active form of GSK-3 that has a mutation at serine 9 (S9A), the inhibitory phosphorylation site, and a catalytically inactive form of GSK-3 (K216R). AR transcriptional activity was not significantly affected by expression of any of these constructs in 22Rv1 cells ( Figure 3a) ; GSK-3 S9A expression did result in a small increase in AR transcriptional activity in CWR-R1 cells (data not shown).
We reasoned that the weak effect of GSK-3 on AR activity might be because endogenous GSK-3 is already active in these cell lines. Therefore, we examined the effects of GSK-3 expression on AR transcriptional activity in LNCaP cells, in which GSK-3 is known to be inactive as a result of phosphorylation at serine 9 (Salas et al., 2004) . When expressed at high levels, wild-type GSK-3 significantly increased AR transcriptional activity in LNCaP cells (Figure 3b , lane 6). Constitutively active GSK-3 increased AR transcriptional activity both at low and high levels of expression ( Figure 3b , lanes 8 and 10, respectively). These results suggest that wildtype GSK-3 is inhibited by phosphorylation at serine 9 in LNCaP cells. Catalytically inactive GSK-3 did not affect AR transcriptional activity ( Figure 3b , lane 12). Taken together, these results support a hypothesis in which GSK-3 positively regulates AR transcriptional activity in prostate cancer cells.
Inhibition of GSK-3 reduces AR transcriptional activity
In order to determine whether the inhibition of AR transcriptional activity by Axin was specific to the effects of Axin on GSK-3 and could not be elicited by other means, we used two further approaches. First, we expressed the proto-oncogene FRAT, which activates the Wnt signalling pathway by binding and sequestering shown). We next determined the effects of FRAT expression on AR transcriptional activity in CWR-R1 cells. As predicted from the experiments using Axin, FRAT inhibited AR transcriptional activity, and the extent of inhibition was significantly reduced when using FRATDC (Figure 4b ). However, FRATDC did repress AR activity to a certain extent, particularly when expressed at higher levels (data not shown). We interpret this result as a manifestation of an indirect effect on GSK-3, since FRATDC can associate with dishevelled, which binds to GSK-3 via Axin (Li et al., 1999) . To summarize, although FRAT and Axin have opposite effects on b-catenin/Tcf transcriptional activity, they both inhibit AR transcriptional activity, and in both cases this requires their GSK-3-binding domains.
In the second approach, we used two commercially available inhibitors of GSK-3, SB415286 and SB216763 (Coghlan et al., 2000) . First we examined the effects of these inhibitors on b-catenin/Tcf-dependent signalling. CWR-R1 cells were transfected with the reporter vector pOT-Luc and treated with GSK-3 inhibitors for 24 h. Consistent with results in other cell types (Coghlan et al., 2000) , both inhibitors increased b-catenin/Tcf-dependent transcriptional activity (Figure 4c ). In contrast, both inhibitors reduced AR transcriptional activity (Figure 4d) , consistent with a model in which endogenous GSK-3 activates AR. Taken together, these results suggest that the inhibitory effects of Axin on AR result from its ability to regulate GSK-3, rather than any function unique to Axin.
Inhibition of GSK-3 reduces prostate cancer cell growth
We next examined the effects of GSK-3 inhibitors on prostate cancer cell growth. We first used CWR-R1 cells, which are hypersensitive to androgens and grow optimally in medium containing 2% FCS, as described previously (Gregory et al., 2001) . CWR-R1 cells were treated with GSK-3 inhibitors and counted over a period of 6 days ( Figure 5a ). Both SB415286 and SB216763 repressed CWR-R1 cell growth. The inhibitory effects of SB216763 on cell growth were maximal at 3 mM (Figure 5b) , which is the same concentration that is optimal for the ability of this drug to protect neurons from apoptotic cell death (Cross et al., 2001) . The inhibitory effects of SB415286 increased with dose up to the maximal dose tested (50 mM; data not shown).
In order to determine whether inhibition of GSK-3 specifically inhibited growth of AR-positive prostate cancer cells, we compared the effects of SB216763 on the growth of CWR-R1, 22Rv1 and LNCaP cells, which express AR, and DU145 and PC3 cells, which do not (Figure 5c ). 22Rv1 and CWR-R1 cells both derive from the CWR22 prostate cancer xenograft but were selected under different growth conditions (Sramkoski et al., 1999; Gregory et al., 2001) . SB216763 similarly reduced the growth of CWR-R1 cells and 22Rv1 cells. In contrast, SB216763 did not significantly affect DU145 or PC3 cell growth, consistent with the possibility that AR is required for the growth inhibitory response. The (1 and 2) , wild-type GSK-3 (3 and 4), GSK-3 S9A (5 and 6) or GSK-3 K216R (7 and 8) plus MMTV-Luciferase, and RSV-b-Gal. AR transcriptional activity was determined in extracts from cells grown in hormonedepleted medium either in the absence (À) or presence ( þ ) of 1 nM R1881. (b) LNCaP cells were transfected with the indicated amounts of empty vector (1 and 2), wild-type GSK-3 (3-6), GSK-3 S9A (7-10) or GSK-3 K216R (11 and 12) plus MMTVLuciferase, and RSV-b-Gal. AR transcriptional activity was determined in extracts from cells grown in hormone-depleted medium either in the absence (À) or presence ( þ ) of 1 nM R1881. AR activity was significantly increased by wild-type GSK-3 at the higher dose (P ¼ 0.02) and by GSK-3 S9A at the lower dose (P ¼ 0.0006) and the higher dose (P ¼ 0.0004). Experiments were done twice in triplicate and error bars indicate standard deviation GSK-3 inhibition represses androgen receptor activity M Mazor et al growth of LNCaP cells was weakly inhibited by SB216763, consistent with the low GSK-3 activity in this cell line. Taken together, these results suggest that inhibition of GSK-3 reduces the growth of AR-positive prostate cancer cells. To determine if inhibition of GSK-3 specifically affected androgen-dependent cell growth, a similar experiment was conducted using 22Rv1 cells grown in hormone-depleted medium in the absence or presence of R1881 (Figure 5d ). Although 22Rv1 cells are able to grow in hormone-depleted medium, their growth can be stimulated by androgens (Sramkoski et al., 1999) . We found that R1881 stimulated the growth of 22Rv1 cells and that this was blocked by treatment with SB216763. However, SB216763 also inhibited hormoneindependent proliferation of 22Rv1 cells to a certain extent.
Inhibition of GSK-3 leads to a reduction in AR protein levels
As a first step in determining the mechanism by which GSK-3 regulates AR transcriptional activity, we examined the expression level of the AR protein in CWR-R1 cells treated with GSK-3 inhibitors. CWR-R1 cells were treated with GSK-3 inhibitors for 24 h and whole-cell extracts were probed for AR by Western blotting (Figure 6 , upper panel). Interestingly, compared with untreated cells (lane 1), the protein level of AR was reduced after treatment with both SB216763 (lane 2) and SB415286 (lane 3). SB415286 appeared to reduce AR protein levels more than SB216763, but reprobing the blot for tubulin (lower panel) indicated that part of this reduction resulted from the effects of this drug on the number of cells. Nevertheless, taking into account 
Association between AR and GSK-3 and its disruption by AX2
In order to determine whether the effects of GSK-3 on AR might involve interactions between these proteins, we examined the possibility that GSK-3 and AR form a complex. AR and myc epitope-tagged GSK-3 were coexpressed in COS7 cells and these proteins were then immunoprecipitated and probed by Western blotting (Figure 7 ). GSK-3 was detected in anti-AR immune precipitates and not in control immune precipitates (Figure 7a) , and AR was detected in anti-GSK-3 immune precipitates and not in control immune precipitates (Figure 7b ). These results support a model in which GSK-3 increases AR transcriptional activity by forming a complex with AR. To determine a possible mechanism for the inhibition of AR activity by Axin, we expressed AX2 or AX2P in COS7 cells together with GSK-3 and AR (Figure 7c ). AR was readily detected in GSK-3 immune precipitates from COS7 cells expressing AX2P. In contrast, we were unable to detect a complex between AR and GSK-3 in cells expressing AX2. This suggests that AX2 inhibits AR transcriptional activity by preventing interaction between GSK-3 and AR and further supports a model in which the association of GSK-3 with AR leads to elevated AR transcriptional activity.
Discussion
Several reports have suggested that b-catenin is a transcriptional coactivator of AR (Truica et al., 2000; Mulholland et al., 2002; Yang et al., 2002) . However, the results from our experiments using Axin and a b-catenin siRNA expression vector to deplete b-catenin suggest that endogenous b-catenin, although highly expressed in prostate cancer cell lines, is not a transcriptional coactivator for endogenous AR. This is in contrast to the results we obtained using transfected AR in HCT116 cells (Figure 1b) . This difference is not due to the AR mutations found in prostate cancer cell lines since we obtained similar results in HCT 116 cells using both wild type and the LNCaP mutant form of AR (unpublished observations).
Our observations highlight the importance of confirming results obtained using ectopically expressed proteins by examining the functions of the endogenous proteins. Clearly, further experiments are necessary to determine the function of endogenous b-catenin in the regulation of AR transcriptional activity. Our results using Axin suggest a role for GSK-3 in the regulation of AR transcriptional activity. The repression of AR activity by Axin required an intact GSK-3-binding domain, since a point mutation in this domain prevented repression. Indeed, expression of the GSK-3-binding domain alone was sufficient to repress AR activity, and the repression of AR by this domain was rescued by coexpression of constitutively active GSK-3. Furthermore, the GSK-3-binding domain of Axin prevented the formation of a GSK-3-AR complex. In support of the hypothesis that Axin inhibits AR transcriptional activity by binding to GSK-3, a second GSK-3-binding protein, FRAT, also repressed AR activity. Further work will be required to determine if endogenous Axin or FRAT play a role in the regulation of AR transcriptional activity, or if the observations we have made solely result from their abilities to sequester GSK-3 when they are overexpressed.
The role of GSK-3 in the regulation of AR transcriptional activity and prostate cancer cell growth was addressed further using GSK-3 inhibitors. The results of these experiments confirmed that GSK-3 activity was required for maximal AR transcriptional activity and proliferation in CWR-R1 cells and 22Rv1 cells. Interestingly, treatment of CWR-R1 cells with GSK-3 inhibitors reduced the level of AR protein. One possible interpretation of these data is that GSK-3 directly phosphorylates AR, and that this phosphorylation increases AR stability. GSK-3 has been shown to regulate the stability of a number of proteins (for references see Frame and Cohen, 2001; Woodgett, 2001; Doble and Woodgett, 2003) . In the majority of cases, phosphorylation by GSK-3 promotes degradation of its target substrate (examples include b-catenin, cyclin D1 and c-myc). However, there are also examples where phosphorylation by GSK-3 promotes protein stability, such as Axin (Yamamoto et al., 1999) . Finally, GSK-3 can have both positive and negative effects on protein stability; for example, it stabilizes nuclear factor-kB1/ p105 under resting conditions and primes p105 for degradation upon TNF-a treatment (Demarchi et al., 2003) . To continue this line of reasoning, the decrease in AR transcriptional activity in cells treated with GSK-3 inhibitors would result from a reduction in AR protein levels, as was observed experimentally (Figure 6 ). Although GSK-3 inhibits the transcriptional activity of many nuclear proteins (for references see Frame and Cohen, 2001; Woodgett, 2001; Doble and Woodgett, 2003) , it activates at least one transcription factor, CREB, by direct phosphorylation (Salas et al., 2003) . It remains to be seen whether GSK-3 activates the AR by direct phosphorylation, and whether this then leads to increased AR protein levels. However, our observation that AR and GSK-3 can be co-immunoprecipitated supports such a possibility.
While this manuscript was in preparation, three other groups reported results from experiments examining the regulation of AR by GSK-3. The first showed that GSK-3 phosphorylates AR and inhibits AR transcriptional activity in transfected COS-1 cells (Salas et al., 2004) . Wang et al. (2004) reported similar results using both COS-1 cells and LNCaP cells. This group also showed that the inhibition of AR by GSK-3 is blocked by lithium chloride. In contrast, Liao et al. (2004) showed that inhibition of GSK-3 using either chemical inhibitors or GSK-3 siRNA reduces AR transcriptional activity. Interestingly, this group also found that depletion of b-catenin by siRNA increased AR transcriptional activity. Our results, obtained using different chemical inhibitors of GSK-3 and using the GSK-3-binding proteins Axin and FRAT, are in agreement with the report from Liao et al. It is possible that the use of different systems for transcription assays (endogenous AR in prostate cancer cell lines as opposed to transfected AR in COS-1 cells) accounts for many of the differences between our results and those suggesting that GSK-3 inhibits AR. However, the results of Wang et al. obtained using LNCaP cells also differ from ours; it is possible that they reflect differences in cell passage number, since this influences regulation of AR activity by Akt, a kinase that can inhibit GSK-3 (Lin et al., 2003) . Akt inhibits AR transcriptional activity in low passage LNCaP cells but enhances AR activity in high passage LNCaP cells. Our experiments were restricted to low passage LNCaP cells (below 25 passages), consistent with the inhibitory effects of Akt on AR activity.
Another important observation made by Wang et al. is that expression of an inducible form of GSK-3 S9A in CWR22 cells (which originate from the same patient as CWR-R1 and 22Rv1 cells) inhibits their growth. This is in contrast to our observations that inhibition of GSK-3 reduces CWR-R1 and 22Rv1 cell growth. The difference might reflect the different methods used to determine cell number (cell counting versus MTT assay).
To summarize, we have used protein and chemical inhibitors of GSK-3 to show that GSK-3 activity is required for maximal activity of the AR. Importantly, our observations that inhibition of GSK-3 leads to a reduction both in AR protein levels and the growth of AR-positive prostate cancer cell lines suggest a novel therapeutic application for GSK-3 inhibitors, which are already under development for diabetes and neurological diseases, in the treatment of prostate cancer.
Materials and methods
Plasmids
GFP-Axin constructs, pOT-Luciferase and RSV-b-Gal have been described (Giannini et al., 2000; Orme et al., 2003) .
MMTV-Luciferase and pSG5 AR were gifts from Charlotte Bevan (Imperial College, London). pTER and pTERbi (van de Wetering et al., 2003) were generously provided by Marc van de Wetering and Hans Clevers (Hubrecht Lab, Utrecht, the Netherlands). The pTER Control 1 siRNA plasmid expresses an siRNA with no known homology to human genes. It was generated using the following oligonucleotides (5 0 -3 0 ): GATCCCCTTCTCCGAACGTGTCACGTTTCAAGAGAA CGTGACACGTTCGGAGAATTTTTGGAAA, GGGAAG AGGCTTGCACAGTGCAAAGTTCTCTTGCACTGTGCA AGCCTCTTAAAAACCTTTTCGA-5 0 . The pTER Control 2 siRNA plasmid expresses an siRNA to a human gene (NM_004626). It was generated using the following oligonucleotides (5 0 -3 0 ): GATCCCCGGACTCGGAACTCGTC TATTTCAAGAGAATAGACGAGTTCCGAGTCCTTTTT GGAAA and GGGCCTGAGCCTTGAGCAGATAAAGTT CTCTT ATCTGCTCAAGGCTCAGGAAAAACCTTTTC GA.
The annealed oligonucleotides were phosphorylated using T4 polynucleotide kinase and ligated into pTER that had been cut with BglII and HinDIII and dephosphorylated using calf intestinal phosphatase.
AX2 (FlagAx-(501-560)), AX2P, FRAT and GSK-3b constructs (Smalley et al., 1999; Franca-Koh et al., 2002; Fraser et al., 2002) were generously provided by Trevor Dale (Cardiff School of Biosciences, UK).
Cell culture and growth assays
Cell lines were from the American Type Culture Collection (Rockville, MD, USA), except for CWR-R1 cells (Gregory et al., 2001) , which were kindly provided by Christopher Gregory (University of North Carolina at Chapel Hill, NC, USA). Cells were grown at 371C, 5% CO 2 . COS7, HEK 293 and HCT 116 cells were grown in DMEM (Invitrogen) with 10% fetal bovine serum (FBS, Invitrogen) and antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin, Sigma). LNCaP, PC3 and DU145 cells were grown in RPMI-1640 medium (Invitrogen) with 10% FBS. CWR-R1 cells were grown in Richter's improved MEM, Zn option (Invitrogen) with 20 ng/ml EGF, 10 mM nicotinamide, 5 mg/ml insulin, 5 mg/ml transferrin, 2% FBS and antibiotics. 22Rv1 cells (Sramkoski et al., 1999) were grown in 1 : 1 RPMI/DMEM with 20% FCS. For experiments using R1881, cells were grown in phenol red-free medium containing 5% (LNCaP, HCT 116 and 22Rv1) or 2% (CWR-R1) charcoal-stripped serum (CSS, First Link Ltd, UK). R1881 (methyltrienolone, DuPont-NEN) was used at 1 nM or 10 nM and control cultures received an equal volume of carrier (ethanol). The GSK-3 inhibitors SB216763 and SB415286 were from Sigma and Biomol Research Labs Inc. (Plymouth Meeting, PA, USA), respectively.
Cell growth assays were conducted according to Gregory et al. (2001) . Briefly, cells (1.5 Â 10 5 /well) were plated in 12-well plates (three wells were used for each condition) and allowed to attach overnight. Carrier or GSK-3 inhibitors were then added and, when indicated, R1881 (or carrier) was added 30 min later. Cells were collected by trypsinization at the indicated times and were counted using a Coulter Counter or using a haemocytometer.
Transfections
All cells were transfected in triplicate in six-well tissue-culture plates. Cells were incubated in serum-free Optimem-1 (Invitrogen) prior to transfection. Cells were transfected using 3.5 ml Plus reagent, 2 ml of lipofectamine and 1 mg DNA per well according to the manufacturers instructions (Invitrogen).
For transcription assays, each well of a six-well plate was transfected with RSV promoter-driven b-galactosidase (200 ng for prostate cancer cell lines, 20 ng for HCT 116 and HEK 293 cells), 300 ng pOT-Luciferase (or pOF-Luciferase, data not shown) or 400 ng MMTV-Luciferase. When necessary, the total amount of DNA was brought to 1 mg using empty plasmid DNA. The amounts of plasmid DNA transfected per well were 200 ng of pSG5 AR (or pSG5 vector as a control), 100 ng of GFP-Axin, GFP-Axin mutants, GFP-FRAT and GFP-FRATDC (or GFP as a control), 600 ng of AX2, AX2P (or pcDNA3 as a control), 50 or 500 ng of GSK-3b constructs (or pcDNA1 vector as a control). For RNAi experiments, cells were first transfected with 1 mg pTERbi or pTER Control 1 or Control 2, and after 24 h they were transfected with reporter vectors together with 200 ng of pTER plasmids. For GSK3b inhibitor experiments, cells were transfected with the reporter plasmids only. In all transfections, after incubating with transfection reagents, cells were grown in their normal growth medium for 40-42 h, or in hormone-depleted medium for 18 h, after which R1881 or ethanol was added and cells were grown for a further 24 h.
Transcription assays
Cells were rinsed in PBS and lysed using Reporter Lysis Buffer (Promega). Luciferase and b-galactosidase assays were performed using the LucLite Plus (Perkin-Elmer Life Sciences) and Galacto-light Plus (Applied Biosystems) kits, respectively, according to manufacturer's instructions. Plates were read on a NXT TopCount Luminometer (Packard Bioscience) and values shown are luciferase activity normalized to b-galactosidase activity.
Cell extraction, immunoprecipitation (IP) and Western blotting
Cells were grown to 50-70% confluence in 100 mm dishes or six-well plates. Lysates were obtained using the following steps: cells were rinsed in cold TBS, lysed in modified RIPA buffer (0.5% deoxycholate, 1% Triton X-100, 20 mM Tris, pH 8.0, 0.1% SDS, 100 mM NaCl, 50 mM NaF) or Nonidet P-40 buffer (1% NP-40, 20 mM Tris, pH 8.0, 150 mM NaCl, 50 mM NaF) for 10 min and centrifuged for 12 min at 15 000 g. Cell extracts were then mixed with an equal volume of SDS sample buffer (Sigma Aldrich) and heated to 951C for 3 min. For IP assays in transfected COS7 cells, cell extracts were prepared using NP-40 lysis buffer, incubated with primary antibody for 1 h on ice. This was followed by 30 min incubation with 20 ml protein A/G-agarose (Cambridge Biosciences) on a rotating wheel in the cold room. After four washes in lysis buffer and one wash in TBS, the beads were resuspended in 10 ml of SDS sample buffer and heated as above. For Western blotting, extracts and IPs were separated by SDS-PAGE, transferred to nitrocellulose membrane and incubated in blocking solution (3% Fraction V BSA, 1% ovalbumin in TBS-T (20 mM Tris, pH 7.5, 100 mM NaCl, 0.1% Tween-20) for 1 h. After probing with antibodies and washing in TBS-T, antigens were visualized using chemiluminescence (ECL, Amersham Biosciences) and exposure to film. Each experiment was repeated at least three times and the results presented are representative.
Antibodies
Western blots were probed using antibodies at 1 : 1000 unless stated otherwise. The following antibodies were used for Western blotting: 9E10 mAb (Sigma Aldrich), P111A rabbit anti-AR (Affinity Bioreagents), anti-b-catenin mAb (Transduction Labs) and anti-g-tubulin mAb (Sigma Aldrich). The following antibodies were used for IP: P110 rabbit anti-AR (Affinity Bioreagents) at 1 : 50, 5 ml anti-GFP polyclonal (Kypta et al., 1996) as a control, 2 mg 9E10 and 2 mg anti-GFP mAb (Roche) as a control. HRP-conjugated secondary antibodies (Jackson Laboratories) were used at 1 : 10000 dilution.
